Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India’s E-Plan To Map Drug Sales – Turning Point For Better Traceability?

Executive Summary

A government plan aimed at putting in place an e-platform to regulate the sale of medicines in India, is expected to bolster end-to-end traceability and help lower the risk of fake drugs in the supply chain. But the platform’s proposed revenue model appears to be a sticking point, at least for now, among other tricky areas.

You may also be interested in...



India’s E-Pharmacy Rules – Balanced And A Leap Of Faith On Patient Data Security?

India’s draft e-pharmacy rules put in place a series of checks and balances to ensure that only genuine e-pharmacies engage in online sales of medicines. Registration and strict record keeping requirements, among other aspects, are mandated under the rules, though it may take a “leap of faith” when it comes to security of patient data, some experts say.

India Reschedules Drug Export Track And Trace Plan

India has deferred the implementation of its track and trace system for pharmaceutical exports - measures that are essentially aimed at curbing the menace of fake products and also enhance supply-chain safety1.

WTO Chief: Pharma Needs To 'Lift The Veil Of Opaqueness' In COVID-19 Vaccine Contracts

WTO director general says pharma could have done more on voluntary licensing for COVID-19 vaccines and also calls for better transparency of pricing and contracts to ensure “a level playing field” when it comes to saving lives.

Topics

UsernamePublicRestriction

Register

PS120331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel